- Bloomberg: CVS Will Exclude Xtandi From Formulary in 2017
- Vivendi-SFR lobbyist nominated to WIPO
- Harvoni & Sovaldi, Xtandi in Top 20 Costliest Medicare Drugs
- Letter from 56 non-profits and experts to Secretary of State John Kerry on pressure on global access to medicines initiatives
- Francis Gurry appoints Sylvie Forbin, lobbyist for Vivendi, as new head of copyright at WIPO
- SCP24:WIPO patent committee adopts robust work program on patents and health, limitations and exceptions and quality of patents
- WIPO Marrakesh Treaty for the blind to come into force September 30, 2016, following ratification by Canada
- Human Rights Council adopts watershed resolution on Access to Medicines
- SCP 24 - A fruitful discussion?
- SCP24: African Group submits revised proposal for a WIPO work program on Patents and Health
In Washington, DC there is a large and growing influence industry. One element of this industry is the thousands of people who register as lobbyists with the Congress. Because of the way disclosure rules are written, this is only a fraction of the persons who are actually employed to influence the Congress or the Executive Branch.
In August, KEI provided comments to USTR regarding the entry of Mexico and Canada into the TPP negotiations. (http://www.keionline.org/node/1542). Today is the public hearing. Right now there are about 35 people in the audience, and a panel of 9 persons from various agencies hearing the testimonies. There are only 10 witnesses in today's hearing, and only three, KEI, PhRMA and IIPA, are speaking on IPR issues.
In April 2012, the WHO released the Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). One of its primary recommendations called upon member states to began formal negotiations on a binding global convention on R&D.
Yesterday I wrote about the USPTO blocking KEI and many other NGOs, blogs and news organizations from their public wifi service. The USPTO says this practice has been discontinued, as of last evening (more here: http://keionline.org/node/1548) but I found the issue interesting enough to follow up a bit. What I have found is more troubling than the initial case described yesterday.
USPTO blocks web access to "Political/Activist Groups" including KEI, ACLU, EFF, Public Citizen, Redstate, DailyKosSubmitted by James Love on 18. September 2012 - 12:32
Update: At 5 pm the USPTO called and said that the public access wifi network was using a filter, provided by a contractor, to block "political activist" sites. This filter was not used by the network providing Internet access for the USPTO staff. After our meeting, the USPTO reviewed its policies, and has removed the filter. USPTO says the filter was implemented by a contractor, and no one we talked to at USPTO was aware of who was being blocked. In any event, the filter has been removed.
Intellectual Property Appellate Board (Chennai) dismisses Bayer's request for a stay on compulsory license for sorafenibSubmitted by thiru on 17. September 2012 - 8:37
On 12 March 2012 the Controller General of Patents,Designs & Trademarks of India issued an order granting a compulsory license under Section 84 of the Patents Act (1970) to Natco in patent number 215758 granted to Bayer covering the anti-drug sorafenib toslyate. KEI filed an affidavit in this compulsory licensing dispute involving Natco and Bayer. Following the issuance of a compulsory license, Bayer requested the Intellectual Property Appellate Board (IPAB) to issue a stay on the compulsory license.
Attached is a PDF of KEI's 31 August 2012 written submission to the French Ministry of Foreign Affairs' national consultation on financing and coordination of research and development for the health needs of developing countries.
Test data protection is a sui generis intellectual property right that was first developed in the 1980s for pharmaceutical drugs, and has been extended recently to biologic drugs and vaccines.
Members of Congress and Governors backing PhRMA/BIO, calling for 12 years data protection for biologic drugs in TPPSubmitted by James Love on 5. September 2012 - 20:15
While the GOP and Democratic conventions highlight the differences between the parties, there are some bipartisan issues, and one of the biggest is taking care of corporate interests.
Data on Chinese patent applications and grants suggests growing gap between political rhetoric and current realitiesSubmitted by James Love on 2. September 2012 - 14:34
The GOP platform mentions China 15 times, including these passages:
Our serious trade disputes, especially China’s failure to enforce international standards for the protection of intellectual property and copyrights, as well as its manipulation of its currency, call for a firm response from a new Republican Administration. . .
USTR will host two public hearings regarding the Trans-Pacific Partnership Agreement (TPPA). The first, to be held on Friday, 21 September 2012, will cover Mexico's participation in the TPPA. The second hearing will be held on Monday, 24 September 2012, and will address Canada's participation in the TPPA.
On 14 September 2011 and 16 September 2011, the World Trade Organization (WTO) undertook a trade policy review of India. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).
The 1980 Bayh-Dole Act is named after two former US Senators, Birch Bayh and Bob Dole. In 2002 both claimed the Bayh-Dole Act march-in provisions were not intended to address cases where prices for inventions are unreasonable, and Senator Bayh repeated this view during a 2004 march-in case involving Abbott patents on ritonavir.
Among the provisions of the Act that suggest otherwise are the following:
Federal Circuit decision again results in three-way split in reasoning in AMP v. USPTO; 2-1 ruling upholds DNA patentsSubmitted by Krista Cox on 16. August 2012 - 12:24
On Thursday, 16 August 2012, the Court of Appeals for the Federal Circuit issued its opinion in the case Association for Molecular Pathology v. US Patent and Trademark Office, again rejecting the plaintiffs' contentions that isolated DNA is not eligible for patent protection. This case surrounds the patent eligibility of isolated DNA, particularly the BRCA1 and BRCA2 genes known to be associated with an individual's susceptibility to breast and ovarian cancer.
As Geneva awakes from its summer slumber post-Jeûne genevois (6 September 2012), the following conferences and negotiations are expected to shape the knowledge governance landscape in the second semester of 2012 at WHO, WIPO and WTO.
World Health Organization
Here are upcoming meetings of the WHO in 2012 of relevance to public heath, innovation and access.